Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen announces positive Phase 2 results for its GLP-1-GIP weight loss drug
MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
GLP-1 weight-loss drugs might help protect kidneys
The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm. In the largest study to date on the effects of the drugs on the kidneys, researchers found GLP-1s help the protect the organs in people with or without diabetes.
West Virginia residents struggle to afford GLP-1 weight loss drugs after state ends subsidy program
In 2020, West Virginia launched a pilot program to subsidize GLP-1 drugs for public employees, but the program was shuttered in March.
5 GLP-1 marketing trends as brands jump on weight loss drug craze
As use of GLP-1 weight loss drugs including Wegovy and Ozempic increases, brands are introducing new offerings.
West Virginia, the most obese state, now can't afford weight loss drugs
West Virginia, the most obese state, now can't afford weight loss drugs
West Virginia ends GLP-1 subsidy program, leaving many unable to afford the drugs
In 2020, West Virginia started a pilot program providing subsidies for GLP-1 weight loss drugs for state employees. It showed promising results, but the program ended in March, leaving many unable to afford the pricey drugs.
2d
on MSN
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs
The Biden administration is looking to expand access to anti-obesity GLP-1 drugs like Ozempic and Wegovy for people who have ...
2d
on MSN
As many as 1 in 5 people won't lose weight with GLP-1 drugs, experts say
About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...
1d
on MSN
Millions more Americans might get access to GLP-1 drugs
Related: Crazy-expensive weight loss drugs may soon see a major change In other news, The Biden Administration is set to ...
STAT
2d
Inside the telehealth-fueled GLP-1 alternative market
The new class of GLP-1 weight loss drugs have been blockbusters since they arrived on the market a few years ago. These ...
News Medical on MSN
20h
GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events
Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.
9d
This new supplement aims to support natural GLP-1 production and gut health
Inno Supps’ Trim Biome™ GLP-1 is designed to support the body’s natural production of GLP-1 through a unique blend of ...
Medscape
1d
GLP-1 Labels Don’t Reflect Trial Exclusions
Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...
13h
The “Holiday Pause” For GLP-1s Is Quickly Approaching — but Is It Safe?
Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Biden
Ozempic
West Virginia
Food and Drug Administration
Glucagon-like peptide-1
Feedback